First Horizon Advisors’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-144
Closed -$3K 2464
2022
Q3
$3K Buy
144
+38
+36% +$1.06K ﹤0.01% 1879
2022
Q2
$3K Buy
+106
New +$3.62K ﹤0.01% 1966
2022
Q1
Sell
-9
Closed 1859
2021
Q4
$0 Sell
9
-169
-95% -$7.64K ﹤0.01% 2297
2021
Q3
$8K Hold
178
﹤0.01% 1597
2021
Q2
$10K Sell
178
-281
-61% -$18.1K ﹤0.01% 1340
2021
Q1
$42K Buy
459
+164
+56% +$16.8K ﹤0.01% 805
2020
Q4
$26K Buy
295
+75
+34% +$6.88K ﹤0.01% 813
2020
Q3
$22K Buy
220
+26
+13% +$2.8K ﹤0.01% 781
2020
Q2
$15K Buy
+194
New +$14.5K ﹤0.01% 884
2019
Q2
Sell
-245
Closed -$12K 1570
2019
Q1
$12K Hold
245
﹤0.01% 993
2018
Q4
$14K Hold
245
﹤0.01% 918
2018
Q3
$16K Buy
+245
New +$14.3K ﹤0.01% 955
2018
Q2
Sell
-150
Closed -$7K 1550
2018
Q1
$7K Hold
150
﹤0.01% 1110
2017
Q4
$7K Hold
150
﹤0.01% 1124
2017
Q3
$6K Hold
150
﹤0.01% 1147
2017
Q2
$5K Buy
+150
New +$4.63K ﹤0.01% 1160
2015
Q2
Sell
-61
Closed -$1K 1427
2015
Q1
$1K Sell
61
-124
-67% -$3.56K ﹤0.01% 1433
2014
Q4
$5K Hold
185
﹤0.01% 1221
2014
Q3
$3K Hold
185
﹤0.01% 1329
2014
Q2
$4K Buy
+185
New +$4.31K ﹤0.01% 1265

Other funds holding EBS

First Horizon Advisors's EBS Position: Q4 2022 in Review

First Horizon Advisors sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 144 shares — an estimated $3K sold.

First Horizon Advisors first reported a position in EBS in Q2 2014 and held it in 20 quarters. The position peaked at $42K in Q1 2021. 196 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

  • First Horizon Advisors reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
  • First Horizon Advisors sold 144 Emergent Biosolutions shares in Q4 2022, an estimated $3K.
  • First Horizon Advisors first reported a position in Emergent Biosolutions in Q2 2014 and held it in 20 quarters.
  • First Horizon Advisors's Emergent Biosolutions position peaked at $42K in Q1 2021.
  • 196 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on First Horizon Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.